

PRESS INFORMATION

Enhancing Diagnostic Confidence for Hepato-Pancreato-Biliary Pathologies: Olympus announces Availability for Purchase of Aplio i800 EUS in Europe

Hamburg, July 18, 2024 – Olympus introduces its new Aplio i800 diagnostic ultrasound system for Endoscopic Ultrasonography (EUS) with the device now available for purchase in Europe.* The processor – manufactured by Canon Medical Systems Corporation and distributed exclusively by Olympus – joins a comprehensive product portfolio of Olympus' Ultrasound Endoscopes and EndoTherapy devices. It is the first output from the [recently announced business alliance](#) between the two global MedTech companies, which aims to provide the market with advanced EUS equipment allowing for high-quality image diagnosis.

The Aplio i800 EUS processor generates ultrasound images to support an accurate and reliable diagnosis of Hepato-Pancreato-Biliary conditions, including liver and pancreatic cancer, as well as respiratory diseases like lung cancer. Diagnosing these diseases is particularly challenging in imaging today due to their complex anatomical locations, the need for high-resolution imaging to detect early-stage abnormalities, and the requirement for precise differentiation between benign and malignant lesions. *"I believe Aplio has opened the doors to a new era of patient care and research innovations in EUS,"* says Prof. Dr. Pietro Fusaroli from the hospital S. Maria della Scaletta in Imola, Italy.

Aiming to advance the Dimensions of Endosonography

First clinical experiences on the Aplio i800 demonstrate that the imaging technology can increase diagnostic confidence for endoscopists during an EUS procedure. Dr. Khanh Do-Cong Pham from the Haukeland University Hospital in Bergen, Norway, summarizes his first experiences with one of its key features: *"Superb Microvascular Imaging (SMI) allows detailed visualization of microvascular structures. With SMI, I feel more confident in my procedures."* SMI expands the range of visible blood flow by revealing low-velocity, microvascular flow, which was not visible before the introduction of this technology. Therefore, it enables physicians to obtain effective and enhanced diagnostic insights when evaluating lesions, cysts, inflammatory diseases, and tumors.

Differential Tissue Harmonic Imaging (D-THI), another of the device's particular features, supports imaging by expanding the effective bandwidth to simultaneously achieve enhanced spatial and contrast resolution, increased penetration, and lower artifact levels for different areas of application: *"With D-THI, endoscopists are assisted in identifying each of the five layers of the gastrointestinal wall with high contrast"*, says Dr. Rodica Gincul from the Jean Mermoz Private Hospital – Ramsay Health in Lyon, France, while her colleague Dr. Bertrand Napoléon emphasizes: *"The higher resolution imaging of Aplio at greater depth through the use of D-THI allows me to safely visualize and reach bile ducts even at very deep locations, improving therapeutic biliary drainage and patient care."*

Finally, the technology of Shear Wave Elastography with 2D mapping capability of elasticity (2DSWE) can display tissue stiffness as a numerical value or color map, enabling endoscopists for a more objective evaluation.

With Aplio i800 EUS now being available in Europe, its market availability will expand to Japan and Oceania next. For more information, please visit [our product website](#).

DISCLAIMER

* The contents of this press release are aimed at healthcare professionals only.

* The healthcare professionals mentioned in this press release have a business relationship with Olympus as part of their contracted market preference test with Aplio i800 EUS.

About Olympus

At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.

For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

For more information, visit www.olympus-europa.com and follow our LinkedIn account: [linkedin.com/company/olympusmedemeal/](https://www.linkedin.com/company/olympusmedemeal/).



For questions or additional information, please contact:

Matthias Gengenbach

Olympus Europa SE & Co. KG

Tel.: +49 151 4236 9420

Email: matthias.gengenbach@olympus.com

www.olympus-europa.com